Skip to main content

Advertisement

SpringerLink
Log in

Implication of MMP-9 and urokinase plasminogen activator (uPA) in the activation of pro-matrix metalloproteinase (MMP)-13

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

We examined whether the expression and activation of pro-matrix metalloproteinase (MMP)-1 varies from that of pro-MMP-13 in the joint fluid of osteoarthritis (OA) and rheumatoid arthritis (RA) patients. To do this, joint fluid was collected from 34 RA and 34 OA patients. The collagenase (pro-MMP-1 and MMP-13, total MMP-1, and MMP-13), gelatinase (total MMP-2 and MMP-9), stromelysin (total MMP-3), matrilysin (total MMP-7), uPA, and tissue inhibitor of MMP (TIMP) levels were measured by ELISA. The level of total MMP-1 in RA joint fluids was similar to that of the OA joint fluid. In contrast, the level of total MMP-13 in the RA group was significantly higher than that of the OA group. Among various MMPs (MMP-2, MMP-3, MMP-7, and MMP-9), only MMP-9 was strongly associated with total MMP-13 in both RA and OA. The level of uPA was also strongly associated with MMP-13 in RA but not OA, while the level of TIMP-1 and TIMP-2 was not significantly different between RA and OA. In conclusion, MMP-9 and uPA might be involved in the activation of pro-MMP-13 through unknown mechanisms in arthritic diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Mor A, Abramson SB, Pillinger MH (2005) The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 115(2):118–128

    Article  PubMed  CAS  Google Scholar 

  2. Weinberg JB, Wortham TS, Misukonis MA, Patton KL, Chitneni SR (1993) Synovial mononuclear phagocytes in rheumatoid arthritis and osteoarthritis: quantitative and functional aspects. Immunol Invest 22(5):365–374

    Article  PubMed  CAS  Google Scholar 

  3. Feldmann M, Brennan FM, Maini RN (1996) Rheumatoid arthritis. Cell 85(3):307–310

    Article  PubMed  CAS  Google Scholar 

  4. Murphy G, Knauper V, Atkinson S, Butler G, English W, Hutton M et al (2002) Matrix metalloproteinases in arthritic disease. Arthritis Res 4(Suppl 3):S39–S49

    Article  PubMed  Google Scholar 

  5. Burrage PS, Mix KS, Brinckerhoff CE (2006) Matrix metalloproteinases: role in arthritis. Front Biosci 11:529–543

    Article  PubMed  CAS  Google Scholar 

  6. Vincenti MP, Brinckerhoff CE (2002) Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 4(3):157–164

    Article  PubMed  CAS  Google Scholar 

  7. Knauper V, Cowell S, Smith B, Lopez-Otin C, O’Shea M, Morris H et al (1997) The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction. J Biol Chem 272(12):7608–7616

    Article  PubMed  CAS  Google Scholar 

  8. Krane SM, Byrne MH, Lemaitre V, Henriet P, Jeffrey JJ, Witter JP et al (1996) Different collagenase gene products have different roles in degradation of type I collagen. J biol chem 271(45):28509–28515

    Article  PubMed  CAS  Google Scholar 

  9. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G (1996) Biochemical characterization of human collagenase-3. J Biol Chem 271(3):1544–1550

    Article  PubMed  CAS  Google Scholar 

  10. Hu B, Kapila YL, Buddhikot M, Shiga M, Kapila S (2000) Coordinate induction of collagenase-1, stromelysin-1 and urokinase plasminogen activator (uPA) by the 120-kDa cell-binding fibronectin fragment in fibrocartilaginous cells: uPA contributes to activation of procollagenase-1. Matrix Biol 19(7):657–669

    Article  PubMed  CAS  Google Scholar 

  11. Nagase H, Suzuki K, Morodomi T, Enghild JJ, Salvesen G (1992) Activation mechanisms of the precursors of matrix metalloproteinases 1, 2 and 3. Matrix Suppl 1:237–244

    PubMed  CAS  Google Scholar 

  12. Murphy G, Knauper V (1997) Relating matrix metalloproteinase structure to function: why the “hemopexin” domain? Matrix Biol 15(8–9):511–518

    Article  PubMed  CAS  Google Scholar 

  13. Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, Monroe HR et al (2008) Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol 9(1):34–46

    Article  PubMed  CAS  Google Scholar 

  14. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M (1996) Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 393(1):101–104

    Article  PubMed  CAS  Google Scholar 

  15. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516

    Article  PubMed  CAS  Google Scholar 

  16. Weiss SJ, Peppin G, Ortiz X, Ragsdale C, Test ST (1985) Oxidative autoactivation of latent collagenase by human neutrophils. Science 227(4688):747–749

    Article  PubMed  CAS  Google Scholar 

  17. Fu X, Kassim SY, Parks WC, Heinecke JW (2003) Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J Biol Chem 278(31):28403–28409

    Article  PubMed  CAS  Google Scholar 

  18. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ (1996) Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 39(9):1576–1587

    Article  PubMed  CAS  Google Scholar 

  19. Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR et al (1996) Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 78(2):161–171

    Article  PubMed  CAS  Google Scholar 

  20. Prince HE (2005) Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers 10(Suppl 1):S44–S49

    Article  PubMed  CAS  Google Scholar 

  21. Miller MC, Manning HB, Jain A, Troeberg L, Dudhia J, Essex D et al (2009) Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. Arthritis Rheum 60(3):686–697

    Article  PubMed  CAS  Google Scholar 

  22. Hayashi N, Nishimura K, Kumagai S (2008) New biomarkers for rheumatoid arthritis. Rinsho Byori 56(4):297–308

    PubMed  CAS  Google Scholar 

  23. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2(10):737–744

    Article  PubMed  CAS  Google Scholar 

  24. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R (2002) The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 169(5):2643–2647

    PubMed  CAS  Google Scholar 

  25. Kim KS, Choi HM, Lee YA, Choi IA, Lee SH, Hong SJ et al (2011) Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int 2011 31(4):543–547

    Google Scholar 

  26. Santos LL, Morand EF, Hutchinson P, Boyce NW, Holdsworth SR (1997) Anti-neutrophil monoclonal antibody therapy inhibits the development of adjuvant arthritis. Clin Exp Immunol 107(2):248–253

    Article  PubMed  CAS  Google Scholar 

  27. Busso N, Peclat V, So A, Sappino AP (1997) Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 56(9):550–557

    Article  PubMed  CAS  Google Scholar 

  28. Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T (2005) The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol 166(3):783–792

    Article  PubMed  CAS  Google Scholar 

  29. Jin T, Tarkowski A, Carmeliet P, Bokarewa M (2003) Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthritis Res Ther 5(1):R9–R17

    Article  PubMed  CAS  Google Scholar 

  30. Drummond AH, Beckett P, Brown PD, Bone EA, Davidson AH, Galloway WA et al (1999) Preclinical and clinical studies of MMP inhibitors in cancer. Ann N Y Acad Sci 878:228–235

    Article  PubMed  CAS  Google Scholar 

  31. Purcell WT, Rudek MA, Hidalgo M (2002) Development of matrix metalloproteinase inhibitors in cancer therapy. Hematol Oncol Clin North Am 16(5):1189–1227

    Article  PubMed  Google Scholar 

  32. Brown PD (1999) Clinical studies with matrix metalloproteinase inhibitors. APMIS 107(1):174–180

    Article  PubMed  CAS  Google Scholar 

  33. Rossello A, Nuti E, Catalani MP, Carelli P, Orlandini E, Rapposelli S et al (2005) A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs. Bioorg Med Chem Lett 15(9):2311–2314

    Article  PubMed  CAS  Google Scholar 

  34. Devel L, Rogakos V, David A, Makaritis A, Beau F, Cuniasse P et al (2006) Development of selective inhibitors and substrate of matrix metalloproteinase-12. J Biol Chem 281(16):11152–11160

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from the Kyung Hee University in 2010 (KHU-20110062).

Author information

Authors and Affiliations

  1. East–West Bone and Joint Research Institute, Kyung Hee University Hospital at KANGDONG, 149 Sangil-dong, Gangdong-gu, Seoul, 134-727, Republic of Korea

    Kyoung Soo Kim, Hyun Mi Choi & Myung Chul Yoo

  2. Division of Rheumatology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Hoeggi-dong, Dongdaemun-gu, Seoul, 130-702, Republic of Korea

    Yeon-Ah Lee

  3. Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital at KANGDONG, 149 Sangil-dong, Gangdong-gu, Seoul, 134-727, Republic of Korea

    Hyung-In Yang

Authors
  1. Kyoung Soo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yeon-Ah Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hyun Mi Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Myung Chul Yoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hyung-In Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyoung Soo Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, K.S., Lee, YA., Choi, H.M. et al. Implication of MMP-9 and urokinase plasminogen activator (uPA) in the activation of pro-matrix metalloproteinase (MMP)-13. Rheumatol Int 32, 3069–3075 (2012). https://doi.org/10.1007/s00296-011-2095-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-2095-4

Keywords

Search

Navigation